CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+18.02%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.06B
AUM Growth
+$1.06B
(-1.1%)
Cap. Flow
-$150M
Cap. Flow
% of AUM
-14.08%
Top 10 Holdings %
Top 10 Hldgs %
37.54%
Holding
501
New
15
Increased
263
Reduced
171
Closed
24
Top Buys
| 1 |
SPDR Gold Trust
GLD
|
$6.59M |
| 2 |
iShares Gold Trust Micro
IAUM
|
$4.62M |
| 3 |
Intuit
INTU
|
$3.73M |
| 4 |
SPDR Gold MiniShares Trust
GLDM
|
$3.6M |
| 5 |
T-Mobile US
TMUS
|
$2.35M |
Top Sells
| 1 |
Apple
AAPL
|
$17.4M |
| 2 |
NVIDIA
NVDA
|
$12.2M |
| 3 |
Microsoft
MSFT
|
$11.5M |
| 4 |
Amazon
AMZN
|
$8.86M |
| 5 |
Broadcom
AVGO
|
$8.43M |
Sector Composition
| 1 | Technology | 38.15% |
| 2 | Healthcare | 22.68% |
| 3 | Communication Services | 12.64% |
| 4 | Consumer Discretionary | 11.62% |
| 5 | Consumer Staples | 3.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Pacira BioSciences
PCRX
$1.22B
| $222K | 0.02% |
9,300
+18
| +0.2% | +$430 |
|
302
Veeva Systems
VEEV
$44.4B
| $222K | 0.02% |
771
| – | – |
|
303
Grifois
GRFS
$6.53B
| $221K | 0.02% |
24,502
+32
| +0.1% | +$289 |
|
304
Franklin Senior Loan ETF
FLBL
$1.2B
| $218K | 0.02% |
+9,000
| New | +$218K |
|
305
Amphastar Pharmaceuticals
AMPH
$1.37B
| $217K | 0.02% |
9,468
-176
| -2% | -$4.04K |
|
306
Dyne Therapeutics
DYN
$1.92B
| $217K | 0.02% |
22,829
+139
| +0.6% | +$1.32K |
|
307
Constellation Brands
STZ
$25.8B
| $214K | 0.02% |
1,314
-1,664
| -56% | -$271K |
|
308
AbCellera Biologics
ABCL
$1.19B
| $206K | 0.02% |
59,949
+178
| +0.3% | +$611 |
|
309
Novavax
NVAX
$1.2B
| $205K | 0.02% |
32,531
+268
| +0.8% | +$1.69K |
|
310
Inspire Medical Systems
INSP
$2.53B
| $204K | 0.02% |
1,574
| – | – |
|
|
CHA
311
Chagee Holdings Limited American Depositary Shares
CHA
$3.42B
| $204K | 0.02% |
+7,818
| New | +$204K |
|
|
VERV
312
DELISTED
Verve Therapeutics
VERV
| $201K | 0.02% |
17,904
+93
| +0.5% | +$1.04K |
|
313
Enliven Therapeutics
ELVN
$1.24B
| $198K | 0.02% |
9,855
+55
| +0.6% | +$1.1K |
|
314
Intellia Therapeutics
NTLA
$1.26B
| $195K | 0.02% |
20,804
+40
| +0.2% | +$375 |
|
315
Collegium Pharmaceutical
COLL
$1.25B
| $191K | 0.02% |
6,456
+141
| +2% | +$4.17K |
|
316
Ardelyx
ARDX
$1.57B
| $188K | 0.02% |
48,053
+243
| +0.5% | +$953 |
|
317
SPDR S&P 500 ETF Trust
SPY
$656B
| $183K | 0.02% |
295
-131
| -31% | -$81.1K |
|
318
Spyre Therapeutics
SYRE
$1.02B
| $181K | 0.02% |
12,122
+35
| +0.3% | +$524 |
|
319
Geron
GERN
$893M
| $180K | 0.02% |
127,922
+170
| +0.1% | +$240 |
|
320
Mineralys Therapeutics
MLYS
$1.94B
| $177K | 0.02% |
13,090
+3,094
| +31% | +$41.9K |
|
321
Zymeworks
ZYME
$1.07B
| $176K | 0.02% |
13,996
+180
| +1% | +$2.26K |
|
322
Nurix Therapeutics
NRIX
$723M
| $174K | 0.02% |
15,312
+90
| +0.6% | +$1.03K |
|
323
Praxis Precision Medicines
PRAX
$980M
| $172K | 0.02% |
4,091
+47
| +1% | +$1.98K |
|
|
AVDL
324
Avadel Pharmaceuticals
AVDL
$1.42B
| $172K | 0.02% |
19,430
+102
| +0.5% | +$903 |
|
325
Natera
NTRA
$23B
| $169K | 0.02% |
+1,000
| New | +$169K |
|